Glaucoma medication use in the surgery and non-surgery groups between the preoperative and postoperative status
| Medications | Preoperative use | Postoperative use | P value* | Discontinued/Started |
|---|---|---|---|---|
| Surgery group | ||||
| β-Blocker, n (%) | 44 (81.4) | 8 (14.8) | <0.001 | 37 (68.5)/1 (1.9) |
| PG analogue, n (%) | 51 (94.4) | 9 (16.7) | <0.001 | 42 (77.8)/0 (0) |
| CAI, n (%) | 47 (87.0) | 12 (22.2) | <0.001 | 37 (68.5)/2 (3.7) |
| α-Agonists, n (%) | 42 (77.8) | 1 (1.9) | <0.001 | 42 (77.8)/1 (1.9) |
| ROCK inhibitor, n (%) | 30 (55.6) | 3 (5.6) | <0.001 | 29 (53.7)/2 (3.7) |
| Non-surgery group | ||||
| β-Blocker, n (%) | 35 (64.8) | 28 (51.8) | 0.065 | 9 (16.7)/2 (3.7) |
| PG analogue, n (%) | 39 (72.2) | 30 (55.6) | 0.023 | 11 (20.4)/2 (3.7) |
| CAI, n (%) | 37 (68.5) | 30 (55.6) | 0.065 | 9 (16.7)/2 (3.7) |
| α-Agonists, n (%) | 27 (50.0) | 21 (38.9) | 0.146 | 9 (16.7)/3 (5.6) |
| ROCK inhibitor, n (%) | 16 (29.6) | 14 (25.9) | 0.727 | 4 (7.4)/2 (3.7) |
*McNemar’s test was used to compare the frequencies of medication use between surgery and non-surgery groups and between preoperative and postoperative status.
CAI, carbonic anhydrase inhibitors; PG, prostaglandin; ROCK, Rho-associated coiled-coil-containing protein kinase.